Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,535 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Paraproteinemia Clear all
Withdrawn Early Phase 1 Interventional

Simvastatin in Overcoming Chemotherapy Resistance in Patients With Relapsed or Refractory Multiple Myeloma

NCT02971410
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Simvastatin
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

NCT00711828
View directory record Official record
Conditions
Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Bortezomib, Rituximab, Cyclophosphamide, Dexamethasone, Questionnaire Administration, Quality-of-Life Assessment
Drug · Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Busulfan Plus Melphalan Conditioning Regimen for Lymphoid Malignancies or Multiple Myeloma

NCT00427765
View directory record Official record
Conditions
Multiple Myeloma, Lymphoma
Interventions
Busulfan, Melphalan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 19, 2012 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients

NCT02566265
View directory record Official record
Conditions
Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Plasma Cell Disorders, MGUS
Interventions
Fluzone High Dose Vaccine, Standard of care/Placebo
Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 21, 2026, 4:22 PM EDT
Terminated Phase 1 Interventional Results available

Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma

NCT02043860
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Total Marrow Irradiation, Autologous Transplant, Melphalan, Filgrastim (G-CSF)
Radiation · Procedure · Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Meloxicam vs Placebo for Mobilization

NCT02003625
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Hematopoietic Stem Cells
Interventions
GCSF, meloxicam, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2020 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 2 Interventional Results available

Study of Decadron, Biaxin, and Pomalidomide in Relapsed/Refractory Myeloma

NCT01159574
View directory record Official record
Conditions
Multiple Myeloma
Interventions
dexamethasone, clarithromycin, Pomalidomide
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 21, 2026, 4:22 PM EDT
Not yet recruiting Phase 1 Interventional

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

NCT07725406
View directory record Official record
Conditions
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Interventions
Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine, Lisocabtagene Maraleucel, Axicabtagene Ciloleucel, Ciltacabtagene Autoleucel, Low-Dose Total Body Irradiation
Drug · Other · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 4:22 PM EDT
Withdrawn Phase 2 Interventional

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

NCT01812720
View directory record Official record
Conditions
Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
carfilzomib, dexamethasone, laboratory biomarker analysis
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Duarte, California • Rochester, Minnesota • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 19, 2016 · Synced Oct 21, 2026, 4:22 PM EDT
Active, not recruiting Phase 2 Interventional

Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis

NCT03315026
View directory record Official record
Conditions
Multiple Myeloma, AL Amyloidosis
Interventions
Siltuximab, The M.D. Anderson Symptom Inventory (MDASI)
Drug · Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
60 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 21, 2026, 4:22 PM EDT
Terminated Phase 3 Interventional Results available

Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

NCT00573391
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Thalidomide, and Dexamethasone, Velcade, Melphalan, and Dexamethasone
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2011 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy and Radiation Therapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

NCT00002510
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, cyclophosphamide, etoposide, mesna, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Temple University
Other
Eligibility
16 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2010 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT00450814
View directory record Official record
Conditions
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions
Cyclophosphamide, Laboratory Biomarker Analysis, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter, Pharmacological Study
Drug · Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 21, 2026, 4:22 PM EDT
Withdrawn Phase 2 Interventional

SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

NCT01329289
View directory record Official record
Conditions
Multiple Myeloma in Relapse, Multiple Myeloma
Interventions
SOM230, Bortezomib, Dexamethasone
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

NCT01864018
View directory record Official record
Conditions
Amyloidosis, Plasma Cell Myeloma
Interventions
Cyclophosphamide, Dexamethasone, Ixazomib Citrate, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 24, 2025 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 1Phase 2 Interventional

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

NCT03997968
View directory record Official record
Conditions
Malignancy, Non-hodgkin Lymphoma, Multiple Myeloma, Breast Cancer, Ovarian Cancer, Soft Tissue Sarcoma, Head and Neck Cancer, DLBCL, Mantle Cell Lymphoma, Follicular Lymphoma, Pancreatic Cancer, CLL, Small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer
Interventions
CYT-0851, CYT-0851 in combination with gemcitabine, CYT-0851 in combination with capecitabine, CYT-0851 in combination with rituximab and bendamustine
Drug
Lead sponsor
Cyteir Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
16
States / cities
San Francisco, California • Stanford, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2024 · Synced Oct 21, 2026, 4:22 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

NCT04923893
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib, Dexamethasone, Lenalidomide, Cilta-cel, Cyclophosphamide, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
19
States / cities
San Francisco, California • New Haven, Connecticut • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Not applicable Interventional

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

NCT00005799
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), B-cell Chronic Lymphocytic Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Renal Cell Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Splenic Marginal Zone Lymphoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, T-cell Large Granular Lymphocyte Leukemia, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Waldenström Macroglobulinemia
Interventions
fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, therapeutic allogeneic lymphocytes, cyclosporine, mycophenolate mofetil, pharmacological study, laboratory biomarker analysis
Drug · Radiation · Procedure + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Duarte, California • Stanford, California • Denver, Colorado + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2019 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 1 Interventional

Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

NCT04439006
View directory record Official record
Conditions
Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Monoclonal B-Cell Lymphocytosis, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Ibrutinib
Other · Drug
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 21, 2026, 4:22 PM EDT
Not listed Phase 1Phase 2 Interventional

T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant

NCT00048464
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Infusion of Activated & Expanded Autologous T Cells
Procedure
Lead sponsor
Xcyte Therapies
Industry
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2006 · Synced Oct 21, 2026, 4:22 PM EDT
Terminated Phase 1 Interventional

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

NCT01609816
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Lymphoma, Multiple Myeloma
Interventions
Dasatinib
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 21, 2026, 4:22 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study of Umbilical Cord Blood Transplantation

NCT00676806
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma, Aplastic Anemia
Interventions
Umbilical Cord Blood After Myeloablative Conditioning, Umbilical Cord Blood After Reduced-Intensity Conditioning
Biological
Lead sponsor
Tufts Medical Center
Other
Eligibility
Up to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 21, 2026, 4:22 PM EDT
Terminated Phase 1 Interventional

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

NCT02110563
View directory record Official record
Conditions
Solid Tumors, Multiple Myeloma, Non-Hodgkins Lymphoma, Pancreatic Neuroendocrine Tumors, PNET, NHL
Interventions
DCR-MYC
Drug
Lead sponsor
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 21, 2026, 4:22 PM EDT
Completed Phase 1 Interventional

XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone Disease

NCT01582295
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cabozantinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 21, 2026, 4:22 PM EDT